secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-118180
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode reports Q3 2023 operating loss of $5.3M; cash runway only into Jan 2024
--------------------------------------------------------------------------------

- Cash $7.5M at Sept 30, 2023, vs $5.0M at Dec 31, 2022; expects runway only into Jan 2024.
- Operating loss $5.3M for Q3 2023 vs $4.3M in Q3 2022; R&D expense $3.3M, G&A $2.0M.
- Dosed first patient in Phase 0 trial of TTX-MC138 in advanced solid tumors; no adverse reactions reported.
- Closed public offering of 16.9M shares/pre-funded warrants at $0.51, gross proceeds ~$8.5M.
- Plans to file IND for Phase I trial of TTX-MC138 and pursue orphan drug designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923118180/0001104659-23-118180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923118180/tm2330726d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer